Corporate Roundtable

The SADS Foundation Corporate Roundtable is comprised of industry partners engaged in developing therapeutics and devices for inherited arrhythmias, that come together in the pre-competitive space to address shared challenges and opportunities in inherited arrhythmia therapy development. The goal is to accelerate the development of meaningful treatments for inherited arrhythmias through open discussion and collaborative engagements.  Membership is open to all sponsors in the inherited arrhythmia or SADS space.  An annual membership fee to support SADS meetings and collaborative activities is required of participants.

SADS Corporate Roundtable incorporates the knowledge and support of large and small companies with the goal of accelerating the development of meaningful treatments for inherited arrhythmias through collaborative efforts on pre-competitive initiatives, thus reducing duplication and gaining resource efficiencies to tackle many of the challenges in drug and device development.